MX2020011397A - Compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2) y el uso de los mismos. - Google Patents

Compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2) y el uso de los mismos.

Info

Publication number
MX2020011397A
MX2020011397A MX2020011397A MX2020011397A MX2020011397A MX 2020011397 A MX2020011397 A MX 2020011397A MX 2020011397 A MX2020011397 A MX 2020011397A MX 2020011397 A MX2020011397 A MX 2020011397A MX 2020011397 A MX2020011397 A MX 2020011397A
Authority
MX
Mexico
Prior art keywords
methods
active compounds
therapeutically active
idh2
treating cancer
Prior art date
Application number
MX2020011397A
Other languages
English (en)
Inventor
Samuel V Agresta
David Schenkein
Hua Yang
Liting Guo
Jianming Wang
Yan Zhou
Zhen Tang
Yanfeng Zhang
Chong-Hui Gu
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2013/081170 external-priority patent/WO2015018060A1/en
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of MX2020011397A publication Critical patent/MX2020011397A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan compuestos inhibidores de isocitrato deshidrogenasa 2 (IDH2) útiles para tratar cáncer y métodos para tratar cáncer, que comprenden administrar a un sujeto en necesidad del mismo, un compuesto descrito en la presente. También se proporcionan formas polimórficas de los compuestos inhibidores de IDH2 caracterizadas por patrones de difracción en polvo por Rayos X, que tienen propiedades fisicoquímicas mejoradas que influyen la tasa de disolución in vivo para propósitos de formulación.
MX2020011397A 2013-08-02 2014-08-01 Compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2) y el uso de los mismos. MX2020011397A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361861884P 2013-08-02 2013-08-02
PCT/CN2013/081170 WO2015018060A1 (en) 2013-08-09 2013-08-09 Crystalline forms of therapeutically active compounds and use thereof
US201461939098P 2014-02-12 2014-02-12
US201461975448P 2014-04-04 2014-04-04
US201462011948P 2014-06-13 2014-06-13
PCT/US2014/049469 WO2015017821A2 (en) 2013-08-02 2014-08-01 Therapeutically active compounds and their methods of use

Publications (1)

Publication Number Publication Date
MX2020011397A true MX2020011397A (es) 2022-08-05

Family

ID=52432592

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016001361A MX2016001361A (es) 2013-08-02 2014-08-01 Compuestos terapeuticamente activos y sus metodos de uso.
MX2020011397A MX2020011397A (es) 2013-08-02 2014-08-01 Compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2) y el uso de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016001361A MX2016001361A (es) 2013-08-02 2014-08-01 Compuestos terapeuticamente activos y sus metodos de uso.

Country Status (21)

Country Link
US (5) US9738625B2 (es)
EP (3) EP3932408A1 (es)
JP (3) JP6742905B2 (es)
CN (3) CN110372670B (es)
AU (2) AU2014295938B2 (es)
BR (1) BR112016002287A2 (es)
CA (1) CA2919382A1 (es)
CL (2) CL2016000263A1 (es)
EA (1) EA030428B1 (es)
ES (1) ES2886211T3 (es)
IL (2) IL243833A0 (es)
MX (2) MX2016001361A (es)
MY (1) MY177994A (es)
NI (1) NI201600022A (es)
PE (1) PE20160840A1 (es)
PH (1) PH12016500164A1 (es)
SA (1) SA516370523B1 (es)
SG (2) SG11201600479WA (es)
TW (2) TWI666208B (es)
UA (1) UA121021C2 (es)
WO (1) WO2015017821A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014295938B2 (en) * 2013-08-02 2018-07-19 Les Laboratoires Servier Therapeutically active compounds and their methods of use
US9694013B2 (en) 2014-09-29 2017-07-04 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CA2975506A1 (en) 2015-02-04 2016-08-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN107922354B (zh) * 2015-05-07 2021-05-25 苏州韬略生物科技有限公司 作为idh2抑制剂的杂环化合物
DK3330258T3 (da) * 2015-07-30 2021-08-16 Chia Tai Tianqing Pharmaceutical Group Co Ltd 1, 3, 5-triazinderivat og fremgangsmåde til anvendelse af samme
AU2016303614A1 (en) 2015-08-05 2018-02-15 Agios Pharmaceuticals, Inc. Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines
SG10201912869WA (en) * 2015-10-15 2020-02-27 Celgene Corp Combination therapy for treating malignancies
JP2018534288A (ja) 2015-10-15 2018-11-22 アジオス ファーマシューティカルズ， インコーポレイテッド 悪性腫瘍の治療のための併用療法
JP6588647B2 (ja) * 2015-10-21 2019-10-09 ノイフォルム・ファーマシューティカルズ・インコーポレイテッドＮｅｕｆｏｒｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 血液悪性腫瘍を治療するための重水素化合物及びその組成物並びに方法
CA3007363A1 (en) 2015-12-04 2017-06-08 Agios Pharmaceuticals, Inc. Methods of treatment of malignancies
WO2017140758A1 (en) 2016-02-19 2017-08-24 Debiopharm International S.A. Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers
CN109069410B (zh) 2016-02-26 2022-05-31 安吉奥斯医药品有限公司 用于治疗血液恶性肿瘤和实体瘤的idh1抑制剂
EP3493809B1 (en) 2016-08-03 2023-08-23 Celgene Corporation Enasidenib for treatment of myelodysplastic syndrome
JP7093764B2 (ja) * 2016-08-03 2022-06-30 セルジーン コーポレイション 骨髄異形成症候群の治療方法
AU2017324844B2 (en) * 2016-09-07 2023-05-11 Celgene Corporation Tablet compositions
KR102601722B1 (ko) * 2017-01-22 2023-11-13 치아타이 티안큉 파마수티컬 그룹 주식회사 1,3,5-트리아진 유도체 염, 결정, 제조 방법, 약학적 조성물 및 그의 용도
WO2018204787A1 (en) 2017-05-05 2018-11-08 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
EP3644999B1 (en) 2017-06-30 2022-12-14 Celgene Corporation Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
CN109467538A (zh) 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
US20220017490A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
US20210403452A1 (en) * 2018-11-02 2021-12-30 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
US20220017489A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Solid dispersions for treatment of cancer
JP2023503842A (ja) 2019-11-14 2023-02-01 セルジーン コーポレーション がんを処置するための小児用製剤
CN114773320A (zh) * 2022-05-29 2022-07-22 重庆医科大学 1,3,5-三嗪化合物及其制备方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390529A (en) 1942-02-03 1945-12-11 Ernst A H Friedheim Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds
JPS58186682A (ja) 1982-04-27 1983-10-31 日本化薬株式会社 セルロ−ス又はセルロ−ス含有繊維材料の染色法
DE3512630A1 (de) 1985-04-06 1986-10-23 Hoechst Ag, 6230 Frankfurt Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern
EP0466647B1 (de) 1990-07-12 1995-11-29 Ciba-Geigy Ag Verfahren zur photochemischen und thermischen Stabilisierung von Polyamid-Fasermaterialien
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
US6274620B1 (en) 1999-06-07 2001-08-14 Biochem Pharma Inc. Thiophene integrin inhibitors
WO2003037346A1 (en) * 2001-10-31 2003-05-08 Cell Therapeutics, Inc. 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer
WO2004009562A1 (en) 2002-07-18 2004-01-29 Janssen Pharmaceutica, Nv Substituted triazine kinase inhibitors
KR101505215B1 (ko) * 2007-04-30 2015-03-23 프로메틱 바이오사이언시즈 인코포레이티드 트리아진 유도체, 상기 유도체를 함유하는 조성물, 및 상기 유도체를 사용한 암 및 자가면역 질환의 치료 방법
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
EP2440050A4 (en) * 2009-06-08 2013-04-03 California Capital Equity Llc TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATION
EP2532659A1 (en) * 2009-07-07 2012-12-12 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
AU2013207289B2 (en) * 2012-01-06 2017-09-21 Les Laboratoires Servier Therapeutically active compounds and their methods of use
EP2824099A4 (en) 2012-03-09 2015-11-11 Carna Biosciences Inc NOVEL TRIAZINE DERIVATIVE
JP6471155B2 (ja) 2013-07-11 2019-02-13 アギオス ファーマシューティカルス，インコーポレーテッド 癌の治療のためのｉｄｈ２変異体阻害剤としてのｎ，６−ビス（アリール又はヘテロアリール）−１，３，５−トリアジン−２，４−ジアミン化合物
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
AU2014295938B2 (en) 2013-08-02 2018-07-19 Les Laboratoires Servier Therapeutically active compounds and their methods of use
US9694013B2 (en) 2014-09-29 2017-07-04 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CA2975506A1 (en) 2015-02-04 2016-08-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
JP6742905B2 (ja) 2020-08-19
IL243833A0 (en) 2016-04-21
AU2018247242A1 (en) 2018-11-01
SG10201709187TA (en) 2017-12-28
MY177994A (en) 2020-09-28
WO2015017821A2 (en) 2015-02-05
TWI666208B (zh) 2019-07-21
ES2886211T3 (es) 2021-12-16
US20180370951A1 (en) 2018-12-27
US10730854B2 (en) 2020-08-04
EP3027193A4 (en) 2017-04-26
JP2019142930A (ja) 2019-08-29
TW201524971A (zh) 2015-07-01
SG11201600479WA (en) 2016-02-26
CN110386922A (zh) 2019-10-29
AU2018247242B2 (en) 2020-03-12
TWI701242B (zh) 2020-08-11
PE20160840A1 (es) 2016-09-22
IL270347B (en) 2021-08-31
UA121021C2 (uk) 2020-03-25
AU2014295938B2 (en) 2018-07-19
CN110372670A (zh) 2019-10-25
JP2021176893A (ja) 2021-11-11
CA2919382A1 (en) 2015-02-05
EA030428B1 (ru) 2018-08-31
SA516370523B1 (ar) 2019-01-10
EP3566706B1 (en) 2021-07-14
NI201600022A (es) 2016-03-16
CL2017002240A1 (es) 2018-04-20
EP3932408A1 (en) 2022-01-05
MX2016001361A (es) 2016-06-14
CN110372670B (zh) 2023-04-07
WO2015017821A3 (en) 2015-04-09
US9738625B2 (en) 2017-08-22
BR112016002287A2 (pt) 2017-08-01
CN105916507A (zh) 2016-08-31
TW201932455A (zh) 2019-08-16
JP2016527279A (ja) 2016-09-08
EP3566706A1 (en) 2019-11-13
CL2016000263A1 (es) 2016-08-19
US20210155603A1 (en) 2021-05-27
AU2014295938A1 (en) 2016-02-18
NZ716226A (en) 2021-08-27
US20240132474A1 (en) 2024-04-25
US20170305885A1 (en) 2017-10-26
PH12016500164A1 (en) 2016-04-25
US20160194305A1 (en) 2016-07-07
EP3027193A2 (en) 2016-06-08
US10093654B2 (en) 2018-10-09
EA201690322A1 (ru) 2016-07-29

Similar Documents

Publication Publication Date Title
PH12016500164A1 (en) Therapeutically active compounds and their methods of use
PH12018501410A1 (en) Therapeutically active compounds and their method of use
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
PH12016501790A1 (en) Pharmaceutical compositions of therapeutically active compounds
NZ746054A (en) Methods of treating cancer
CR20200479A (es) COMPUESTOS TERAPÉUTICAMENTE ACTIVOS Y SUS MÉTODOS DE USO (Divisional 2016-0069)
MY178621A (en) Deuterated cftr potentiators
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
MX350432B (es) Compuestos terapeuticamente activos y sus metodos de empleo.
PH12016502352A1 (en) Pharmaceutical composition
PH12016502353A1 (en) Pharmaceutical composition
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
CA2908957C (en) Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
NZ707090A (en) Synthetic lethality and the treatment of cancer
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
WO2016106357A8 (en) Combination of raf inhibitors and aurora kinase inhibitors
MX365021B (es) Composicion para tratar o prevenir enfermedades ocasionadas por permeabilidad vascular, que contiene como ingrediente activo imatinib o una sal farmaceuticamente aceptable del mismo.
MX2015017124A (es) Combinacion de ro5503781, capecitabina y oxaliplatino para la terapia para el cancer.
IN2013DE03665A (es)